Secondary surgical cytoreduction for advanced ovarian carcinoma

New England Journal of Medicine

Volumn 351, Issue 24, 2004, Pages

  Rose, Peter G ^a,b   Nerenstone, Stacy ^c,d   Brady, Mark F ^e   Clarke Pearson, Daniel ^f   Olt, George ^g   Rubin, Stephen C ^h   Moore, David H ⁱ   Small, James M ^j,k   Mackey, Denise ^l  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d HARTFORD HOSPITAL   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UniPath   (United States)

^k Colorado Gynecologic Oncology ^*  (United States)

^l Gynecol Oncol Grp Admin Office   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NEUROPATHY; OVARY CARCINOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REOPERATION; THROMBOCYTOPENIA; TINNITUS; TREATMENT CONTRAINDICATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; POSTOPERATIVE COMPLICATIONS; SURVIVAL ANALYSIS;

EID: 19744365355     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa041125     Document Type: Article

References (30)

1. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. In: Symposium on ovarian cancer. Monograph series no. 42. Washington, D.C.: National Cancer Institute, 1975:101-4.
2. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-20.
3. Delgado G, Oram DH, Petrilli ES. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol 1984;18:293-8.
4. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 1990;38:203-9.
5. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-80.
6. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
7. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-7.
8. Muggia FM, Braly PS, Brady MJ, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:106-15.
9. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
10. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
11. Ng LW, Rubin SC, Hoskins WJ, et al. Aggressive chemosurgical debulking in patients with advanced ovarian cancer. Gynecol Oncol 1990;38:358-63.
12. Lawton FG, Redman CW, Luesley DM, Chan KK, Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol 1989;73:61-5.
13. Wils J, Blijham G, Naus A, et al. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 1986;4:1068-73.
14. Neijt JP, Aartsen EJ, Bouma J, Heintz AP, van Lent M, van Lindert AC. Cytoreductive surgery with or without preceding chemotherapy in ovarian cancer. Prog Clin Biol Res 1985;201:217-23.
15. Kaju KS, McKinna JA, Barker GH, Wiltshaw E, Jones JM. Second-look operations in the planned management of advanced ovarian carcinoma. Am J Obstet Gynecol 1982;144:650-4.
16. Vogel SE, Seltzer V, Calanog A, et al. "Second-effort" surgical resection for bulky ovarian cancer. Cancer 1984;54:2220-5.
17. van der Burg MEL, vanlent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629-34.
18. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.
19. Blessing JA. Design, analysis and interpretation of chemotherapy trials in gynecologic cancer. In:. Deppe G, ed. Chemotherapy of gynecologic cancer. New York: Alan R. Liss, 1984:68-72.
20. Winter WE, Maxwell L, Tian C, et al. Prognostic factors for advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:412. abstract.
21. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer; a multivariate analysis of 704 patients. Ann Oncol 1997;8:963-8.
22. Reynolds T. Why randomized surgical oncology trials are so scarce. J Natl Cancer Inst 1999;91:1182-3.
23. Prefontaine M, Gelfand AT, Donovan JT, Powell JL. Reproducibility of tumor measurements in ovarian cancer: a study of interobserver variability. Gynecol Oncol 1994;55:87-90.
24. Boente MP, Yeh K, Hogan WM, Ozols RF. Current status of staging laparotomy in colorectal and ovarian cancer. Cancer Treat Res 1996;82:337-57.
25. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Whanon JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991;42:146-50.
26. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999;72:93-9.
27. Surwit E, Childers J, Atlas M, et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996;6:356-61.
28. Onnis A, Marchetti M, Padovan P, Castellan L. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynaecol Oncol 1996;17:393-6.
29. Vergote I, DeWever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998;71:431-6.
30. Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 1999;93:21-4.